4.5 Article

Patients with epilepsy: Cognitively compromised before the start of antiepileptic drug treatment?

期刊

EPILEPSIA
卷 51, 期 1, 页码 48-56

出版社

WILEY
DOI: 10.1111/j.1528-1167.2009.02195.x

关键词

Epilepsy; Newly diagnosed epilepsy; Neuropsychology; Cognitive functioning; Cognition

资金

  1. Health Technology Assessment
  2. MRC [G0400615]
  3. Pfizer
  4. UCB Pharma
  5. Glaxo SmithKline
  6. Janssen-Cilag
  7. Novartis
  8. Sanofi-Synthelabo
  9. Medical Research Council [G0400615] Funding Source: researchfish

向作者/读者索取更多资源

P>Purpose: To compare the cognitive profile of newly diagnosed untreated epilepsy patients with healthy volunteers using a comprehensive neuropsychological test battery. Methods: A total of 155 untreated patients with newly diagnosed epilepsy, and no known brain pathology, were assessed before the start of treatment with antiepileptic medication. Their scores across the neuropsychological measures were compared with 87 healthy volunteers from the general population equated for age and sex. Results: After adjusting for age, sex, and education, patients with epilepsy performed significantly worse than healthy volunteers on 6 of 14 cognitive measures, particularly in the domains of memory and psychomotor speed. Cognitive performance was not related to the number of seizures, type of epilepsy, or mood. When an impairment index was calculated, 53.5% patients had a least one abnormal score [> 2 standard deviations (SD) below the control mean] on the test battery compared with 20.7% of healthy volunteers. Discussion: Newly diagnosed untreated patients with epilepsy are cognitively compromised before the start of antiepileptic drug medication. The domains most affected are memory and psychomotor speed. More than one-half of the patients had at least one abnormal test score across the test battery. There were no differences in epilepsy-related or mood variables between those who demonstrated dysfunction and those that did not.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据